Bristol-Myers' Kidney Transplant Drug Nulojix Receives FDA Green Signal

by Kathy Jones on  June 16, 2011 at 7:32 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US Food and Drug Administration has approved Bristol-Myers' Nulojix, which is a drug that prevents organ rejection in kidney transplant patients.
 Bristol-Myers' Kidney Transplant Drug Nulojix Receives FDA Green Signal
Bristol-Myers' Kidney Transplant Drug Nulojix Receives FDA Green Signal

The new drug is to be used with other immunosuppressive drugs such as basiliximab, mycophenolate mofetil, and corticosteroids. Nulojix belongs to a class of drugs called selective T-cell costimulation blockers.

These drugs prevent the body from rejecting the newly transplanted kidney. The FDA approval follows the successful completion of two Phase-3 studies that included more than 1,200 patients. These studies compared two dose regimens of Nulojix with another immunosuppressant, cyclosporine.

Nulojix is an effective drug, but also carries a boxed warning regarding a risk of post-transplant lymphoproliferative disorder (PTLD), which is a type of cancer of the white blood cells.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Signature Drug Toxicity Kidney Disease Kidney Kidney Health Stones in Urinary Tract Renal Tubular Acidosis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive